Founder David R. Liu Headquarters Cambridge | Founded 2004 Type of business private | |
 | ||
Industry Health care
Biotechnology Key people Michael D. Taylor
Nick K. Terrett Products Ensemblins™ (under development) Website ensembletherapeutics.com | ||
Ensemble Therapeutics Corporation is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2004 by Harvard chemist David R. Liu, the company develops and is attempting to bring to market synthetic macrocycle drugs, that is, compounds with a characteristic macrocyclic ring structure, under the trademark Ensemblins. If successful, Ensemblins would be a new class of drugs between small molecules and biologics. An orally active antagonist to Interleukin 17 has been demonstrated in animal models.
Contents
Management
John Ripple became chief executive officer in 2013. Nick K. Terrett has been the chief scientific officer since 2006. Founder David R. Liu chairs the scientific advisory board.
Ownership
Ensemble is principally owned by Flagship Ventures, a venture capital firm whose founder, Noubar Afeyan, chairs its board. Other investors include ARCH Venture Partners, CMEA, Harris & Harris, Kisco Ltd., and Boston University. As of 2012, Ensemble has raised $38.5 million of equity financing.
Partnerships
Ensemble has entered into partnerships that allow its macrocycle libraries to be accessed for the purpose of affinity screening drug discovery against targets that are otherwise difficult to address. Partner firms include Novartis, Alexion, Boehringer Ingelheim, Genentech, Bristol-Myers Squibb, and Pfizer.